Sök

Colorectal cancer IHC portfolio

Roche colorectal IHC assay panel slide icon
Deliver diagnostic confidence with the Roche colorectal cancer IHC portfolio

Roche offers a robust menu of tools to aid in colorectal cancer diagnostics. The Roche portfolio of assays, including IHC diagnostic assays, deliver the high sensitivity and specificity pathology professionals need.

 

Fully-automated IHC/ISH staining

 

Roche antibodies are ready to use on the fully-automated BenchMark IHC/ISH staining platforms, reducing the time-to-result and resources required with manual or semi-automated solutions.

KONTAKTA OSS

Featured assays

MLH-1
VENTANA anti-MLH1 (M1) Mouse Monoclonal Primary Antibody
 

VENTANA anti-MLH1 (M1) Mouse Monoclonal Primary Antibody is used to qualitatively identify human DNA mismatch repair (MMR) protein MLH1, expressed in the nucleus of normal proliferating cells.1 Loss of MLH1 is associated with MMR deficiency and microsatellite instability (MSI) in colorectal and other cancers.2,3,4,5

  • Mouse monoclonal antibody
  • Loss of MLH1 in solid tumors may help identify patients eligible for certain immunotherapies1
  • Loss of MLH1 in colorectal cancer may help identify patients with probable Lynch syndrome1
  • Fully automated
PMS2 (EPR3947) Rabbit Monoclonal Antibody
VENTANA anti-PMS2 (A16-4) Mouse Monoclonal Primary Antibody
 

VENTANA anti-PMS2 (A16-4) Mouse Monoclonal Primary Antibody is used to qualitatively identify human PMS2 protein, expressed in the nucleus of normal proliferating cells.6 Loss of PMS2 is associated with MMR deficiency and microsatellite instability (MSI) in colorectal and other cancers.6

  • Mouse monoclonal antibody
  • Loss of PMS2 in solid tumors may help identify patients eligible for certain immunotherapies6
  • Loss of PMS2 in colorectal cancer may help identify patients with probable Lynch syndrome6
  • Fully automated
MSH2 (G219-1129)
VENTANA anti-MSH2 (G219-1129) Mouse Monoclonal Primary Antibody
 

VENTANA anti-MSH2 (G219-1129) Mouse Monoclonal Primary Antibody is used to qualitatively identify human MSH2 protein, expressed in the nucleus of normal proliferating cells.7 Loss of MSH2 is associated with MMR deficiency and microsatellite instability (MSI) in colorectal and other cancers.7

  • Mouse monoclonal antibody
  • Loss of MSH2 in solid tumors may help identify patients eligible for certain immunotherapies7
  • Loss of MSH2 in colorectal cancer may help identify patients with probable Lynch syndrome7
  • Fully automated
CONFIRM anti-MSH6 (44)
VENTANA anti-MSH6 (SP93) Rabbit Monoclonal Primary Antibody
 

VENTANA anti-MSH6 (SP93) Rabbit Monoclonal Primary Antibody is used to qualitatively identify human MSH6 protein, expressed in the nucleus of normal proliferating cells.8 Loss of MSH6 is associated with MMR deficiency and microsatellite instability (MSI) in colorectal and other cancers.9,10

  • Rabbit monoclonal antibody
  • Loss of MSH6 in solid tumors may help identify patients eligible for certain immunotherapies8
  • Loss of MSH6 in colorectal cancer may help identify patients with probable Lynch syndrome8
  • Fully automated
BRAF V600E (VE1)
VENTANA anti-BRAF V600E (VE1) Mouse Monoclonal Primary Antibody
 

VENTANA anti-BRAF V600E (VE1) Mouse Monoclonal Primary Antibody is used to qualitatively identify BRAF V600E protein as an aid to differentiate between sporadic colorectal cancer and probable Lynch syndrome, as expression is tightly linked with hypermethylation of the MLH1 promoter and subsequent loss of MLH1 expression in sporadic colorectal cancer.11,12,13,14

  • Mouse monoclonal antibody
  • Expression of BRAF V600E mutant protein in the presence of MLH1 loss in colorectal cancer cells differentiates sporadic cancer from probable Lynch syndrome14
  • Fully automated
  • >95% concordance with Sanger sequencing14
CDX-2 (EPR2764Y)
CDX-2 (EPR2764Y) Rabbit Monoclonal Antibody
 

CDX-2 is a caudal-related homeobox transcription factor whose expression in the adult is normally restricted to the intestinal epithelium.15 Loss of CDX-2 protein expression has been correlated with loss of differentiation in colorectal cancers.16 Anti-CDX-2 antibody has been useful in distinguishing gastrointestinal origin of metastatic adenocarcinomas and carcinoids.17

  • Rabbit monoclonal antibody
  • Fully automated
Take an in-depth look at our full colorectal cancer IHC assay portfolio.

Search our product catalogs and documentation library in eLabDoc.

Visit DiaLog
Roche colorectal cancer IHC panel in eLabDoc

  1. VENTANA anti-MLH1 (M1) Mouse Monoclonal Primary Antibody package insert.1015763EN Rev D. 2021.
  2. Poulogiannis G, Frayling IM, Arends MJ. DNA mismatch repair deficiency in sporadic colorectal cancer and Lynch syndrome. Histopathology 2010; 56: 167-179.
  3. Lanza G, Gafà R, Maestri I, Santini A, Matteuzzi M, Cavazzini L. Immunohistochemical pattern of MLH1/MSH2 expression is related to clinical and pathological features in colorectal adenocarcinomas with microsatellite instability. Mod Pathol 2002; 15: 741-749.
  4. Cortes-Ciriano I, Lee S, Park WY, et al: A molecular portrait of microsatellite instability across multiple cancers. Nat Commun 2017; 8:15180.
  5. Hause RJ, Pritchard CC, Shendure J, et al: Classification and characterization of microsatellite instability across 18 cancer types. Nat Med 2016;22:1342-1350.
  6. VENTANA anti-PMS2 (A16-4) Mouse Monoclonal Primary Antibody Package Insert.1015766EN Rev D. 2021.
  7. VENTANA anti-MSH2 (G219-1129) Mouse Monoclonal Primary Antibody Package Insert.1015765EN. Rev D. 2021.
  8. VENTANA anti-MSH6 (SP93) Rabbit Monoclonal Antibody Package Insert.1015764 Rev D. 2021.
  9. Miyaki M, Konishi M, Tanaka K et al. Germline mutation of MSH6 as the cause of hereditary nonpolyposis colorectal cancer. Nature Genet 1997:17:271–272.
  10. Akiyama Y, Sato H, Yamada T et al. Germ-line mutation of the hMSH6/GTBP gene in an atypical hereditary nonpolyposis colorectal cancer kindred. Cancer Res 1997: 57:3920–3923.
  11. Deng G, Bell I, Crawley S, Gum, J et al. BRAF Mutation Is Frequently Present in Sporadic Colorectal Cancer with Methylated hMLH1, But Not in Hereditary Nonpolyposis Colorectal Cancer. Clinical Can Res 2004:10:191-195.
  12. Toon C, Chou A, DeSilva K, Chan J et al. BRAFV600E immunohistochemistry in conjunction with mismatch repair status predicts survival in patients with colorectal cancer. Mod Path 2014:27:644-650.
  13. Koinuma, K, Shitoh K, Miyakura Y, Furukawa T. et al. Mutations of BRAF Are Associated With Extensive hMLH1 Promoter Methylation in Sporadic Colorectal Carcinomas. Int J Cancer 2004:108:237-242.
  14. Capper D, Voigt A, Bozukova G et al. BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer. Int J Cancer 2013;133:1624-1630.
  15. Suh, E et al. A homeodomain protein related to caudal regulates intestine-specific gene transcription, Mol. Cell. Biol 1994:14:7340–7351.
  16. Bae, J. et al. Loss of CDX2 expression is associated with poor prognosis in colorectal cancer patients. World J Gastroenterol 2015: 21(5): 1457-1467.
  17. CDX-2 (EPR2764Y) Rabbit Monoclonal Antibody Package insert. EN Rev. 5.0v1.2018.

Related Topics